Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA - Evseev, D; Kalinina, I; Raykina, E (Int J Hematol, 2021)